Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Atherosclerosis. 2015 Jul 15;242(1):211–217. doi: 10.1016/j.atherosclerosis.2015.07.018

Figure 3.

Figure 3

Personalization of Benefit and Harm with Coronary Artery Calcium Score and Liver Fat. Numbers of persons needed to treat (NNT) with statins to avoid one hard cardiovascular disease (CVD) event and numbers persons needed to harm (NNH) with statins to cause one additional incident type 2 diabetes (T2D) case in categories of coronary artery calcium score (CAC) and fatty liver (defined as quartile 1 of liver attenuation) or normal liver (quartiles 2–4 of liver attenuation). Subgroups with CVD risk reduction high benefit (low NNT) are outlined in green (both bottom and right middle cells). Subgroups with high risk of T2D are shaded in red (right column). Overlapping regions appear brown.